Soligenix, Inc.
$1.38
▼
-0.87%
2026-04-21 09:31:00
www.soligenix.com
NCM: SNGX
Explore Soligenix, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$14.22 M
Current Price
$1.38
52W High / Low
$6.23 / $1
Stock P/E
—
Book Value
$0.77
Dividend Yield
—
ROCE
-213.96%
ROE
-2.35%
Face Value
—
EPS
$-2.14
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
13
Beta
1.94
Debt / Equity
6.77
Current Ratio
2.39
Quick Ratio
2.39
Forward P/E
-1.32
Price / Sales
—
Enterprise Value
$3.96 M
EV / EBITDA
-0.34
EV / Revenue
—
Rating
Strong Buy
Target Price
$15
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Maravai LifeSciences Holdings, Inc. | $3.61 | — | $928.01 M | — | -17.71% | -48.59% | $4.11 / $1.67 | $1.46 |
| 2. | Intensity Therapeutics, Inc. | $5.21 | — | $13.46 M | — | -100.14% | -1.57% | $50 / $4.63 | $4.7 |
| 3. | Nuvectis Pharma, Inc. | $8.33 | — | $235.78 M | — | -149.75% | -1.88% | $11.52 / $5.55 | $0.72 |
| 4. | Syndax Pharmaceuticals, Inc. | $23.78 | — | $2.1 B | — | -66.67% | -1.62% | $25.59 / $8.58 | $0.74 |
| 5. | Sol-Gel Technologies Ltd. | $70 | — | $228.83 M | — | -31.74% | -23.72% | $97.97 / $4.11 | $8.19 |
| 6. | BioAtla, Inc. | $5.69 | — | $7.61 M | — | 732.7% | 543.76% | $71.5 / $3.92 | $-0.6 |
| 7. | 4D Molecular Therapeutics, Inc. | $10.07 | — | $535.53 M | — | -30.52% | -27.57% | $12.34 / $2.88 | $8.78 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -3.47 M | -2.58 M | -2.76 M | -3.31 M | -3.71 M | — |
| Net Profit | -2.9 M | -2.53 M | -2.7 M | -3.24 M | -2.99 M | — |
| EPS in Rs | -0.28 | -0.25 | -0.26 | -0.31 | -0.29 | -0.78 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0.25 M |
| Operating Profit | -11.85 M | -9.46 M | -7.67 M | -14.11 M |
| Net Profit | -11.08 M | -8.27 M | -6.14 M | -13.8 M |
| EPS in Rs | -1.08 | -0.8 | -0.6 | -1.34 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 9.24 M | 8.97 M | 9.8 M | 14.28 M |
| Total Liabilities | 3.94 M | 4.85 M | 7.27 M | 16.75 M |
| Equity | 5.29 M | 4.12 M | 2.52 M | -2.47 M |
| Current Assets | 8.85 M | 8.83 M | 9.51 M | 13.85 M |
| Current Liabilities | 3.7 M | 4.85 M | 6.15 M | 16.52 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -10.27 M | -8.4 M | -8.6 M | -12.65 M |
| Investing CF | -0.01 M | 0 M | 0 M | -0.01 M |
| Financing CF | 10.39 M | 7.76 M | 3.66 M | 0.08 M |
| Free CF | -10.27 M | -8.4 M | -8.6 M | -12.66 M |
| Capex | -0.01 M | — | — | -0.01 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | -100% | — | — |
| Earnings Growth % | -34.62% | 55.5% | — | — |
| Profit Margin % | — | — | -5519.34% | — |
| Operating Margin % | — | — | -5642.41% | — |
| Gross Margin % | — | — | -120.33% | — |
| EBITDA Margin % | — | — | -5642.44% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2024-06-06 | 1:0.0625 |
| 2023-02-10 | 1:0.0666667 |